- FDA Approves Neurotoxic Flu Drug For Infants Less Than One (GreenMedInfo, Dec 27, 2012):
Whereas the flu is self-limiting, the FDA’s capacity for bad decisions is not…
The recent decision by the FDA to approve the use of the antiviral drug Tamiflu for treating influenza in infants as young as two weeks old, belies an underlying trajectory within our regulatory agencies towards sheer insanity.
Tamiflu, known generically as oseltamivir, has already drawn international concern over its link with suicide deaths in children given the drug after its approval in 1999. In fact, in 2004, the Japanese pharmaceutical company Chugai added “abnormal behavior” as a possible side effect inside Tamiflu’s package. The FDA also acknowledged in its April, 2012 “Pediatric Postmarket Adverse Event Review” of Tamiflu that “abnormal behavior, delirium, including symptoms such as hallucinations, agitation, anxiety, altered level of consciousness, confusion, nightmares, delusions” are possible side effects.[i]
Recent animal research on Tamiflu has found that the infant brain absorbs the drug more readily than the adult brain,[ii] [iii]lending a possible explanation for why neuropsychiatric side effects have been observed disproportionately in younger patients.
Tags: Big Pharma, Brain, Children, Drugs, FDA, Flu, Global News, Government, Health, neurotoxic, neurotoxicity, Pharmaceutical Industry, Politics, Tamiflu, toxic, toxicity, U.S.





![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)